 Fallopian Tube Neoplasms
"Fallopian Tube Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
| Descriptor ID |
D005185
|
| MeSH Number(s) |
C04.588.945.418.365 C13.351.500.056.390.390 C13.351.937.418.365
|
| Concept/Terms |
Fallopian Tube Neoplasms- Fallopian Tube Neoplasms
- Fallopian Tube Neoplasm
- Neoplasm, Fallopian Tube
- Neoplasms, Fallopian Tube
Fallopian Tube Cancer- Fallopian Tube Cancer
- Cancer, Fallopian Tube
- Cancers, Fallopian Tube
- Fallopian Tube Cancers
- Cancer of the Fallopian Tube
|
Below are MeSH descriptors whose meaning is more general than "Fallopian Tube Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Fallopian Tube Neoplasms".
This graph shows the total number of publications written about "Fallopian Tube Neoplasms" by people in this website by year, and whether "Fallopian Tube Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fallopian Tube Neoplasms" by people in Profiles.
-
Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 08 10; 40(23):2568-2577.
-
Renner CM, Visetsouk MR, Kreeger PK, Masters KS. Multispectral Staining and Analysis of Extracellular Matrix. Methods Mol Biol. 2022; 2424:105-119.
-
Lusk H, Burdette JE, Sanchez LM. Models for measuring metabolic chemical changes in the metastasis of high grade serous ovarian cancer: fallopian tube, ovary, and omentum. Mol Omics. 2021 12 06; 17(6):819-832.
-
Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
-
O'Cearbhaill RE, Deng W, Chen LM, Lucci JA, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384)?+ OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):393-399.
-
Wolsky RJ, Price MA, Zaloudek CJ, Rabban JT. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa? Int J Gynecol Pathol. 2018 May; 37(3):262-274.
-
Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):433-8.
-
Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013 Mar; 23(3):417-21.
-
Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2011 Nov; 21(8):1422-7.
-
Andreopoulou E, Chen T, Liebes L, Curtin J, Blank S, Wallach R, Hochster H, Muggia F. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):457-63.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|